Healios K.K. to Present at Jefferies Global Healthcare Conference

Core Insights - Healios K.K. is set to present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 4:00 PM GMT [1] - The company is a leading clinical stage biotechnology firm in Japan, focusing on regenerative medicine through stem cell technology [3] Company Overview - Healios K.K. specializes in developing therapies for diseases lacking effective treatment options, utilizing both somatic stem cells and induced pluripotent stem (iPS) cells [3] - The company is advancing MultiStem® (HLCM051), a proprietary cell product derived from adult bone marrow, which has shown anti-inflammatory and immunomodulatory properties [3] - MultiStem has been tested in late-stage clinical trials with hundreds of patients, demonstrating safety and suggested efficacy across multiple indications [3] - Healios is also developing HLCN061, a next-generation NK cell treatment for solid tumors, which has shown robust anti-tumor efficacy in animal models and is preparing for initial human testing [3] - The company has established a gene-edited "universal donor" iPS cell line aimed at developing treatments in various fields, including immuno-oncology and ophthalmology [3] - Healios was founded in 2011 and has been publicly listed on the Tokyo Stock Exchange since 2015 under the code 4593 [3]